Back to search

Article

Real-Life Benefit and Costs of First Line Pembroli-zumab for Advanced NSCLC—A Propensity-Score Matched Case-Control Study

2024-12-24

Abstract excerpt

<h4>Background: </h4> Immune checkpoint inhibitor (ICI) therapy using Pembrolizumab alone or in combina-tion with chemotherapy (CHT) is a widely used first-line standard for advanced NSCLC without ac-tionable driver mutations. However, a considerable fraction of patients does not respond to ICI, and associated costs are significant. We aimed to investigate the real-life benefit and costs of first line Pembrolizuma...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
95588460-2abd-5b13-92df-87642ed5542e
DOI
10.20944/preprints202412.2034.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-Life Benefit and Costs of First Line Pembroli-zumab for Advanced NSCLC—A Propensity-Score Matched Case-Control StudyDOI 10.20944/preprints202412.2034.v1
Immune Checkpoint Inhibitor without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A real-world retrospective studySemantic proximity
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.Semantic proximity
First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness AnalysisSemantic proximity
A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profilingSemantic proximity
The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in ScotlandSemantic proximity
Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.Semantic proximity
Albumin Paclitaxel Plus Platinum With or Without Pembrolizumab for Metastatic Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Retrospective Multicenter StudySemantic proximity
Optimal Treatment Strategies for EGFR Mutant Advanced Lung Adenocarcinoma Patients with Targeted Therapy Resistance and Correlation Analysis of PD-L1 Expression with ICI EfficacySemantic proximity
Effectiveness and Durable Outcomes with Second-Line Immunotherapy in Advanced NSCLC in Real World Practice in IndiaSemantic proximity
First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness AnalysisSemantic proximity
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity
Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients.Semantic proximity
Select a neighboring publication to make it the new centre.